NCT06663046 - Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2029

Conditions

Multiple MyleomaRefractory and Relapsed Multiple Myeloma

Interventions

BIOLOGICAL

Single dose injection of certain dose of UWD-00B

Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells

Trial Locations (1)

710061

RECRUITING

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an